Acute Phase Response Cancer Cardiovascular Disease Cytokines, Chemokines, and Growth Factors Neurology Toxicology Infectious Disease Immunoglobulin Isotyping Signal Transduction

Bio-Plex Pro Human Immunotherapy 20-Plex Panel

MAGNETIC SEPARATION ENABLED

GM-CSF, IFN-γ, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-13, IL-15, IL-17A, IL-18, IP-10, MCP-1/CCL2 (MCAF), MIG, MIP-1α, MIP-1β, RANTES, TNF-α

- All-in-one 20-plex panel
- Single-level quality control
- Magnetic workflow



High-Performance Multiplex Screening Immunoassays for Research and Drug Discovery

Cytokines and chemokines are extracellular mediators and regulators within a signaling network between cells and are key modulators of immune response, participating in cell signaling via a complex network of interactions. This panel integrates a network of biologically relevant cytokines and chemokines in a single assay, enabling you to interrogate 20 biomarkers simultaneously. This screening tool allows targeted screening of analytes specific to immune response. It is ideal for use during development of immunotherapies and assessing their efficacy and safety profiles during clinical trials. All assays in this panel have gone through a rigorous validation process to ensure the data are accurate and reproducible.

Assay Features

- Comprehensive panel coverage
- Broad dynamic range
- Best-in-class performance
- Reduced turnaround time
- Reproducible results
- Streamlined data analysis
- Flexibility

Rigorous Assay Validation

All Bio-Plex Pro Assays undergo rigorous evaluation that includes the following parameters:

- Specificity (cross-reactivity)
- Accuracy (recovery) in key sample matrices
- Inter- and intra-assay precision
- Sensitivity (limit of detection [LOD])
- Assay working range (lower and upper limits of quantification [LLOQ/ULOQ])
- Linearity of dilution
- Parallelism and matrix effect
- Performance characteristics in real samples (Figure 1)



Assay Performance Definitions

The following parameters are indicative of assay performance, as shown in Table 1.

- Assay working range the range of concentrations within which the assay is precise and accurate.
 Boundaries of the assay working range are defined by the LLOQ and ULOQ
- Precision the percentage coefficient of variation (%CV) at concentrations within the assay working range
- Accuracy (recovery) percentage of the observed concentration relative to the expected concentration of a known amount of analyte within the assay working range
- Sensitivity (LOD) the concentration of analyte for which the fluorescence intensity signal is 2 standard deviations above the background signal

- Linearity of dilution determines to what extent the dosage response above LLOQ can be diluted and measured accurately within the assay working range (Table 2)
- Parallelism determines if a diluent matrix used to construct a standard curve is biologically comparable to the diluent matrix used for sample preparation. This ensures that the recombinant calibrator shares the same binding characteristic to the antibodies as the native molecules (Table 3 and Figure 2)




Fig. 1. Analyte detectability. Four hundred and twenty test samples from six laboratories, including culture media, cancer serum, stimulated peripheral blood mononuclear cells, whole blood, and human immunodeficiency virus plasma, were run on the assay. The average analyte detectability for the panel is >80%. Analyte detectability is defined as the percentage of analytes detected within the working assay range for all samples in a study.

	Assay Wor	king Range,	Assay Sensitivity,			
	pg/ml		pg/ml	Mean Intra-Assay	Mean Inter-Assay	Singleplex Bead
Analyte	LLOQ*	ULOQ*	LOD*	%CV*	%CV*	Region
GM-CSF	0.48	7,846	0.19	4.3	2.2	34
IFN-γ	1.57	25,665	1.05	3.1	3.6	21
IL-2	1.29	21,178	0.75	1.7	2.5	38
IL-4	0.19	3,064	0.09	3.2	1.9	52
IL-5	3.63	59,499	0.86	2.3	2.3	33
IL-6	0.38	6,244	0.34	2.2	3.0	19
IL-7	1.92	31,475	1.22	2.7	3.9	74
IL-8	0.85	13,992	0.36	3.2	2.8	54
IL-10	1.06	17,427	0.69	2.3	3.4	56
IL-13	0.31	5,157	0.22	3.1	2.7	51
IL-15	12.42	203,426	12.82	2.8	4.1	73
IL-17A	2.44	39,972	1.16	2.4	1.4	76
IL-18	0.66	10,892	0.31	2.9	2.2	42
IP-10	3.41	34,953	1.43	2.8	6.0	48
MCP-1 (MCAF)	0.53	8,755	0.44	3.2	3.4	53
MIG	3.16	32,365	1.39	4.4	4.2	14
MIP-1α	0.12	1,218	0.06	4.5	4.2	55
MIP-1β	1.41	1,439	1.41	3.4	2.5	18
RANTES	16.72	26,467	3.98	3.0	6.7	37
TNF-α	3.33	54,566	1.13	3.5	3.0	36

Table 1. Representative performance characteristics.

* The LLOQ, ULOQ, LOD, and inter-assay precision %CV are mean data determined from three independent multiplex assays in a serum-based matrix. Intra-assay %CV is derived from one representative assay. LLOQ and ULOQ are defined as the boundary standard curve points within which the performance specifications of individual standard points were met for a 10% intra-assay CV and recovery range of 70–130%. Data were generated using the magnetic workflow with the Bio-Plex Pro Wash Station.

Table 2. Linearity of dilution.*

Analyte Linear Dilution Range		Analyte	Linear Dilution Range
GM-CSF	1–1:2,187	IL-15	1:3–1:81
IFN-γ	1–1:2,187	IL-17A	1–1:243
IL-2	1–1:2,187	IL-18	1–1:9
IL-4	1–1:2,187	IP-10	1–1:81
IL-5	1–1:729	MCP-1 (MCAF)	1–1:81
IL-6	1–1:81	MIG	1–1:81
IL-7	1:9–1:729	MIP-1α	1:3–1:243
IL-8	1–1:243	MIP-1β	1:3-1:242
IL-10	1–1:729	RANTES	1–1:9
IL-13	1–1:2,187	TNF-α	1–1:729

* Linearity of dilution determines whether the dosage response of the analyte is linear within the working assay range. A 50-plex recombinant standard was spiked into a serum sample, which was previously diluted 1:4 with standard diluent HB, then serially diluted seven times. Table 2 shows the sample dilution range where the dosage response is linear. The range is defined as the recovery of calculated concentrations within 70–130%.

Table 3. Parallelism.*

Analyte	%CV	
IL-18	15	%
IP-10	12	Recoverv.
MCP-1 (MCAF)	13	O B C O
MIG	9	ű
RANTES	19	

* Parallelism "is to ascertain that the binding characteristic of the endogenous analyte to the antibodies is the same as for the calibrator" (Andreasson et al. 2015). One human serum sample with high endogenous analytes was serially diluted (1:2). Table 3 shows the %CV of quantitation results from 25% serum samples and the subsequent dilutions.




Fig. 2. Parallelism with MIG analyte. Representative percentage recovery data from Table 3. Upper limit (\blacksquare); human serum sample (\blacklozenge); lower limit (\blacktriangle).

Ordering Information

Cotolog #	Description	Catalog #	Description
Catalog #	1	9	Description
12007975	Bio-Plex Pro Human Immunotherapy 20-Plex Panel , 1 x 96-well, includes coupled magnetic capture beads, premixed detection antibodies, standards, quality control, detection antibody diluent HB, standard diluent HB, sample diluent HB, assay buffer, 10x wash buffer, streptavidin- phycoerythrin, 96-well flat bottom plate, sealing tape, and instructions, for the detection of GM-CSF, IFN-γ, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-13, IL-15, IL-17A, IL-18, IP-10, MCP-1/CCL2 (MCAF), MIG, MIP-1α, MIP-1β, RANTES, TNF-α	Standards 12007919	Bio-Plex Pro Human Cytokine Screening Panel Standards , 1 vial, lyophilized mixture of 50 standard analytes, includes basic FGF, CTACK, eotaxin, G-CSF, GM-CSF, GRO-α, HGF, ICAM-1, IFN-α2, IFN-γ, IL-1α, IL-1β, IL-1ra, IL-2, IL-2Rα, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-16, IL-17A, IL-18, IP-10, LIF, MCP-1/CCL2 (MCAF), MCP-3, M-CSF, MIF, MIG, MIP-1α, MIP-1β, β-NGF, PDGF-BB, RANTES, SCF, SCGF-β, SDF-1α, TNF-α, TNF-β, TRAIL, VCAM-1, VEGF-A
	Human Singleplex Sets		,
171B5018M	GM-CSF Set		ns and Accessories
171B5019M	IFN-γ Set	30034376	Bio-Plex Pro Wash Station, microplate wash station for
171B5003M	IL-2 Set		magnetic bead-based assays, includes magnetic plate carrier,
171B5004M	IL-4 Set		waste bottle, 2 buffer bottles
171B5005M	IL-5 Set	171020100	Bio-Plex Handheld Magnetic Washer, includes magnetic
171B5006M	IL-6 Set		washer and adjustment hex tools for use in manual wash
171B5007M	IL-7 Set	171005001	steps for all Bio-Plex Magnetic Assays
171B5008M	IL-8 Set	171025001	Bio-Plex Pro Flat Bottom Plates , pkg of 40 x 96-well plates,
171B5010M	IL-10 Set		for use with Bio-Plex Pro Wash Stations when using magnetic
171B5012M	IL-13 Set		bead-based assays
171B5013M	IL-15 Set	Software	
171B5014M	IL-17A Set	171001510	Bio-Plex Data Pro Software with Bio-Plex Manager
171B5020M	IP-10 Set		Software, Bio-Plex Data Pro Software (5 seats) for
171B5021M	MCP-1 Set		multi-experiment analysis and advanced data visualization
171B6015M	MIG Set		and Bio-Plex Manager Software (5 seats) for instrument
171B5022M	MIP-1α Set		data evaluation and optimization; CDs and security HASP
171B5023M	MIP-1β Set		key included
171B5025M	RANTES Set	171001513	Bio-Plex Data Pro Software, 5 seats, for multi-experiment
171B5026M	TNF- α Set		analysis and advanced data visualization
_		171STND01	Bio-Plex Manager Software, 1 user desktop license, for

Reagent Kits

12005846 **Bio-Plex Pro Reagent Kit III**, 10 x 96-well, includes detection antibody diluent HB, standard diluent HB, sample diluent HB, assay buffer, 10X wash buffer, streptavidin-phycoerythrin, flat bottom plate, and sealing tape

Reference

Andreasson U et al. (2015). A practical guide to immunoassay method validation. Front Neurol 6, 179.

analysis of Bio-Plex data and generation of protocols; does

Visit **bio-rad.com/Bio-PlexImmunotherapyKit** for more information.

not operate the instrument

BIO-RAD and BIO-PLEX are trademarks of Bio-Rad Laboratories, Inc. in certain jurisdictions.

The Bio-Plex Suspension Array System includes fluorescently labeled microspheres and instrumentation licensed to Bio-Rad Laboratories, Inc. by the Luminex Corporation.

All trademarks used herein are the property of their respective owner.



Bio-Rad Laboratories, Inc.

Life Science Group
 Web site
 bio-rad.com
 USA 1 800 424 6723
 Australia 61 2 9914 2800
 Austria 43 01 877 89019
 Belgium
 32 03 710 53 00
 Brazil 55 11 3065 7550

 Canada 1 905 364 3435
 China 86 21 6169 8500
 Czech Republic 36 01 459 6192
 Denmark 45 04 452 10 00
 Finland 35 08 980 422 00

 France 33 01 479 593 00
 Germany 49 089 3188 4393
 Hong Kong 852 2789 3300
 Hungary 36 01 459 6190
 India 91 124 4029300

 Israel 972 03 96 0500
 Italy 39 02 49486600
 Japan 81 3 6361 7000
 Korea 82 2 3473 4460
 Mexico 52 555 488 7670
 The Netherlands 31 0 318 540 666

 New Zealand 64 9 415 2280
 Norway 47 0 233 841 30
 Poland 36 01 459 6191
 Portugal 351 21 472717
 Rusia 7 495 721 14 04

 Singapore 65 6415 3188
 South Africa 36 01 459 6193
 Spain 34 091 49 06 580
 Sweden 46 08 555 127 00
 Switzerland 41 0617 17 9555

 Taiwan 886 2 2578 7189
 Thailand 66 2 651 8311
 United Arab Emirates 971 4 8187300
 United Kingdom 44 01923 47 1301

19-0526 0719 Sig 0119

